ADVERTISEMENT

Research & Development

Mind The Gap: Europe Pharma R&D Spend Loses Ground On US While China Climbs

Mind The Gap: Europe Pharma R&D Spend Loses Ground On US While China Climbs

While Europe and the US had similar levels of R&D expenditure until 2014, the gap is widening and China is coming up on the rails, according to a new report from EFPIA, which warns that a coherent life sciences strategy for Europe would help stop the decline.

Canada’s Data Linkage Roadmap To Drive Decision Making For Rare Disease Drugs

Canada’s Data Linkage Roadmap To Drive Decision Making For Rare Disease Drugs

The roadmap sets out eight steps to help registry teams link data from registry records with administrative health services data.

The Future Of Inflammation: The Inflammasome And Beyond

The Future Of Inflammation: The Inflammasome And Beyond

Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.

Abbisko And Merck KGaA MANEUVER Pimicotinib Towards Approval

Abbisko And Merck KGaA MANEUVER Pimicotinib Towards Approval

Pimicotinib’s Phase III data in tenosynovial giant cell tumor are better than its rivals but the fight for a small number of patients will be fierce.

Muscling Into The Obesity Market

Muscling Into The Obesity Market

At a recent conference, executives from Boehringer and Amgen laid out their expectations for the future of obesity and how they intend to navigate the changes.

Neoadjuvant Cancer Immunotherapy Set For Takeoff, Fueled By Strong Data

Neoadjuvant Cancer Immunotherapy Set For Takeoff, Fueled By Strong Data

Dreams of a future with early curative treatments drives wave of drug development in pre-surgical and perioperative treatment in many tumor types.

Vertex Readies For Major Readouts, With Data Due Soon In Big Pain Market

Vertex Readies For Major Readouts, With Data Due Soon In Big Pain Market

Q3 revenue beat consensus and Vertex raised its guidance, but R&D progress was the main highlight across the cystic fibrosis, kidney disease, type 1 diabetes and, particularly, pain pipeline.

Verona’s Ohtuvayre Off To Flying Start

Verona’s Ohtuvayre Off To Flying Start

Sales of its novel COPD therapy in its first quarter on the market were more than double consensus estimates, and Verona sees more to come.

The Practice-Changing Drugs That Will Graduate In 2025

The Practice-Changing Drugs That Will Graduate In 2025

A wealth of new therapies are set to successfully graduate from the pipeline in 2025. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and treatments that will meaningfully change how diseases are treated.

Compass Antidepression Psychedelic Still On Course Despite Delays

Compass Antidepression Psychedelic Still On Course Despite Delays

The company, now the most advanced clinically in the psychedelic space after the rejection of Lykos's MDMA-based post-traumatic stress disorder drug, is cutting its workforce by a third and narrowing its research focus after shifting the timeline for its late-stage depression candidate.